United States· US:82432-101_52b8bd13-33cb-4def-a172-8853a39fe4c4
nalmefene hydrochloride
A nalmefene product containing nalmefene hydrochloride, registered in United States by Chengdu Shuode Pharmaceutical Co., Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nalmefene is registered in 14 of 19 countries.
Countries holding a registration under ATC N07BB05 (nalmefene), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Nalmefene · ATC N07BB05
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nalmefene costs, country by country.
Normalised to the WHO defined daily dose (18 mg), the median price runs from $3.31 in France to $6.33 in Switzerland — a ×1.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nalmefene · price per daily dose (18 mg)
USD · FX 28 Sept 2026
- CH Switzerland$6.33
- FR France$3.31
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NALMEFENE HYDROCHLORIDE
- Manufacturer
- Chengdu Shuode Pharmaceutical Co., Ltd
- Country
- United States (US)
- ATC code
- N07BB05
- ATC class
- Nalmefene
- Defined daily dose
- 18 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1182432-101-01
- ndc1182432101011 VIAL, GLASS in 1 CARTON (82432-101-01) / 1 mL in 1 VIAL, GLASS
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for nalmefene.
Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nalmefene · interactions on record
5 records
- 4 moderate
- 1 minor
Most severe, free to view
- Methylnaltrexone bromideA06AH01moderate
- NaloxegolA06AH03moderate
- NaldemedineA06AH05moderate
- GlimepirideA10BB12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nalmefene in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSELINCROH. Lundbeck A/S, Valby
- SwitzerlandSelincro, FilmtablettenLundbeck (Schweiz) AG
- SpainSELINCRO 18 MG COMPRIMIDOS RECUBIERTOS CON PELICULAH. Lundbeck A/S
- BelgiumSelincro 18 mgH. Lundbeck
- IrelandSelincro 18 mg film-coated tabletsH. Lundbeck A/S
- IcelandSelincroH. Lundbeck A/S*
- NetherlandsSelincro 18 mg, filmomhulde tabletH. Lundbeck A/S
- NorwaySelincroH.Lundbeck
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Germany · Nalfino
- France · Nalmefene Biogaran
- Iceland · Selincro
- Norway · Selincro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/aaa70602-be61-4c24-b667-4261898f0e24 GET /v1/drugs/aaa70602-be61-4c24-b667-4261898f0e24?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS",
"source": "ndc",
"strength": ".1",
"substance": "NALMEFENE HYDROCHLORIDE",
"productndc": "82432-101",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "ANDA216007",
"marketing_category": "ANDA"
}See everything about nalmefene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.